Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Abstract

Study hypothesis: increased DNA damage by PARP inhibition will complement the anti-tumor activity of the immune checkpoint inhibitor, durvalumab. Study status: 18 patients with recurrent NSCLC have been enrolled, including patients previously treated with immunotherapy. Sixteen patients are evaluable for response. Two partial responses have been observed. The study is designed to enroll 20 patients initially. If after interim analysis, the median PFS is 3.5 months or less, the study will close to accrual. If PFS is greater than 3.5 months, accrual will continue until 37 patients are enrolled.